{"pageContent": "Results presented at the American Urological Association 2020 Virtual Meeting demonstrated that of men who received prior RT or surgery for localized prostate cancer, those that had RT were found to have a 32% higher risk of developing castrate-resistant disease.", "metaData": {"source": "Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment\nhttps://pubmed.ncbi.nlm.nih.gov/34435699/"}}